Roche Holding AG - Bearer Shares RO

SWX: RO | ISIN: CH0012032113   17/05/2024
258,20 CHF (+0,55%)
(+0,55%)   17/05/2024
Grafiek Roche Holding AG - Bearer Shares Grafiek Roche Holding AG - Bearer Shares

Roche Holding AG - Bearer Shares in het nieuws

16 mei 2024 · [Ad hoc announcement pursuant to Art. 53 LR] Roche reports positive Phase I results for its dual GLP-1/GIP receptor agonist CT-388 in people with obesity · Persbericht

15 mei 2024 · Roche announces FDA approval of one of the first HPV self-collection solutions in the U.S., expanding access and screening options to help eliminate cervical cancer · Persbericht

24 april 2024 · [Ad hoc announcement pursuant to Art. 53 LR] Roche sales increase by 2% (CER) in first quarter with both divisions growing in high single digit ex COVID-19 · Persbericht

19 april 2024 · FDA approves Roche’s Alecensa as the first adjuvant treatment for people with ALK-positive early-stage lung cancer · Persbericht

17 april 2024 · Roche’s subcutaneous OCREVUS one-year data demonstrates near-complete suppression of clinical relapses and brain lesions in patients with progressive and relapsing forms of MS · Persbericht

15 april 2024 · [Ad hoc announcement pursuant to Art. 53 LR] Roche’s Columvi meets primary endpoint of overall survival in people with relapsed or refractory diffuse large B-cell lymphoma in Phase III STARGLO study · Persbericht

11 april 2024 · Roche granted FDA Breakthrough Device Designation for blood test to support earlier Alzheimer's disease diagnosis · Persbericht

26 maart 2024 · Roche receives FDA approval for the first molecular test to screen for malaria in blood donors · Persbericht

12 maart 2024 · Roche Annual General Meeting 2024 · Persbericht

12 maart 2024 · Assemblée générale 2024 de Roche · Persbericht

Profiel Roche Holding AG - Bearer Shares

CEO: Severin Schwan

Aandelen Roche Holding AG - Bearer Shares

Beurswaarde: 192,36 miljard CHF

Effecten: 106,69 miljoen

Winst per aandeel (12 maand):  PLUS

Mijn selecties